Toward Molecular Imaging-Driven Drug Development in Oncology

Elisabeth G. E. de Vries; T. H.  Oude Munnink; Marcel A. T. M. van Vugt; Wouter B. Nagengast

doi:10.1158/2159-8274.CD-11-0051

Toward Molecular Imaging-Driven Drug Development in Oncology

Elisabeth G. E. de Vries^*, T. H. Oude Munnink, Marcel A. T. M. van Vugt, Wouter B. Nagengast

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

13 Downloads (Pure)

Abstract

With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed. Cancer Discovery; 1(1); 25-8. (C) 2011 AACR.

Original language	English
Pages (from-to)	25-28
Number of pages	4
Journal	Cancer Discovery
Volume	1
Issue number	1
DOIs	https://doi.org/10.1158/2159-8274.CD-11-0051
Publication status	Published - Jun-2011

Keywords

METASTATIC BREAST-CANCER
TOMOGRAPHIC ASSESSMENT
PROSTATE-CANCER

Access to Document

10.1158/2159-8274.CD-11-0051

Toward Molecular Imaging–Driven Drug Development in Oncology Final publisher's version, 2.83 MBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{f9c946f29b01430d8be78b0e9bc08305,

title = "Toward Molecular Imaging-Driven Drug Development in Oncology",

abstract = "With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed. Cancer Discovery; 1(1); 25-8. (C) 2011 AACR.",

keywords = "METASTATIC BREAST-CANCER, TOMOGRAPHIC ASSESSMENT, PROSTATE-CANCER",

author = "{de Vries}, {Elisabeth G. E.} and {Oude Munnink}, {T. H.} and {van Vugt}, {Marcel A. T. M.} and Nagengast, {Wouter B.}",

year = "2011",

month = jun,

doi = "10.1158/2159-8274.CD-11-0051",

language = "English",

volume = "1",

pages = "25--28",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Toward Molecular Imaging-Driven Drug Development in Oncology

AU - de Vries, Elisabeth G. E.

AU - Oude Munnink, T. H.

AU - van Vugt, Marcel A. T. M.

AU - Nagengast, Wouter B.

PY - 2011/6

Y1 - 2011/6

N2 - With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed. Cancer Discovery; 1(1); 25-8. (C) 2011 AACR.

AB - With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed. Cancer Discovery; 1(1); 25-8. (C) 2011 AACR.

KW - METASTATIC BREAST-CANCER

KW - TOMOGRAPHIC ASSESSMENT

KW - PROSTATE-CANCER

U2 - 10.1158/2159-8274.CD-11-0051

DO - 10.1158/2159-8274.CD-11-0051

M3 - Review article

SN - 2159-8274

VL - 1

SP - 25

EP - 28

JO - Cancer Discovery

JF - Cancer Discovery

IS - 1

ER -

Toward Molecular Imaging-Driven Drug Development in Oncology

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this